Evotec AG has reached a milestone triggering a $2.6 million payment in its research alliance with Boehringer Ingelheim. The milestone was for the transition of an oncology program into lead optimization. Dr. Mario Polywka, chief operating officer of Evotec, said, “This is the 11th milestone achieved as part of this alliance with Boehringer Ingelheim and the second against an oncology target. We continue to enjoy a very rich scientific partnership with Boehringer Ingelheim and look forwa...